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Abstract
Background: Brugada syndrome (BrS) is a rare cardiac arrhythmia characterized by sudden death 
associated with electrocardiogram patterns characterized by incomplete right bundle-branch block and 
ST-segment elevations in the anterior precordial leads. This syndrome predominantly is seen in younger 
males with structurally normal hearts. Mitochondrial variants particularly mt-tRNA mutations, are hot 
spots that lead to cardiological disorders. Previous studies have shown  that mutations in mitochondrial 
tRNA genes play an important causal or modifying role in BrS. The present study aims to evaluate the 
involvement of mitochondrial tRNA genes in arrhythmogenic BrS.
Methods: In this study, 40 Iranian patients were investigated for the presence of the mutations in  
6 mitochondrial tRNA genes (tRNA Ile, Met, Gln, Asn, Ala and Trp) by PCR-SSCP analysis. 
Results: There were 4 mutations in tRNA genes, that for first time, were found in BrS patients 
and these mutations were not in controls. Three of them were heteroplasmic and located in tRNAGln 
(T4377A) and tRNAMet (G4407A and C4456T) which were assessed as pathogenic mutations. A homo-
plasmic variant (5580T > C) in tRNATrp gene was located within the junction region between tRNATrp 
and tRNAAla genes. This mutation may disturb the processing of mt-tRNATrp.  
Conclusions: The results of this study suggest that mutations in mitochondrial tRNA genes might lead 
to deficiencies in translational process of critical proteins of the respiratory chain and potentially lead to 
BrS in Iranian subjects. (Cardiol J 2018; 25, 1: 113–119)
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Introduction
Brugada syndrome (BrS) (OMIM 601144) is 
inherited in an autosomal dominant manner and is 
characterized by a variable ST segment elevation 
in the right precordial electrocardiogram (ECG) 
leads and has a high incidence of ventricular 
arrhythmias and sudden death in patients with 
structurally normal hearts [1]. Interestingly, 
ST segment elevation may disappear after intra-
venous isoprenaline or exercise [2]. A definitive 
diagnosis can be made when a type of ST segment 
elevation is observed in more than 1 right precor-
dial lead (V1 to V3) in the presence or absence of 
a sodium channel-blocking agent, and in conjunction 
with one of the following: documented ventricular 
fibrillation, polymorphic ventricular tachycardia, 
a family history of sudden cardiac death at less 
than 45 years of age, coved-type ECGs in family 
members, syncope, or abnormal nocturnal respi-
ration [3, 4].
The ECG pattern of BrS may be present at 
imaging or may become apparent only under spe-
cial conditions (such as vagal stimulation, fever or 
exposure to a sodium channel blocking drug) [5, 6]. 
The clinical diagnosis of BrS is determined when 
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it is associated with a previous history of syncope 
or sudden cardiac death [7]. 
This syndrome typically manifests during 
adulthood, with a mean age at first arrhythmic 
event ranging between 22 and 65 years, but also 
occurs in infants and children [8]. Over 90% of 
these cases had been in male patients. Symptoms 
of BrS occur mostly at night and seem to be most 
prevalent in Southeast Asia and Japan [9]. Screen-
ing of some families with the Brugada phenotype 
has revealed distinct mutations in the SCN5A gene, 
which encodes the pore-forming alpha-subunit 
of the cardiac sodium channel [10]. In patients 
with this syndrome, researchers found missense 
mutations in SCN5A and assessed the functional 
significance of these mutations on cardiac sodium 
channel characteristics [11]. Alterations seemed to 
be associated with an increase in inward sodium 
current during the action potential upstroke [12].
At the present time, it is known that an in-
creasing number of human diseases is found to be 
associated with point mutations in mitochondrial 
tRNA genes [13]. The heart is highly dependent 
on oxidative energy generated in mitochondria and 
this suggests that defects in ion channels which 
are adenosine triphosphate (ATP)-sensitive, are 
responsible for channelopathy diseases such as 
heart arrhythmia [14]. 
Also, it is distinguished that tRNAMet, tRNAIle, 
tRNATrp and tRNAGln genes were hot spots for 
cardiovascular diseases [15]. Yet, most of studies 
focused on nucleic genes and family-based screen-
ing in arrhythmia, and knowledge of mitochondrial 
tRNA genes and population-based Iranian patients 
with arrhythmia especially BrS, was limited. Thus, 
we have paid special attention to determine the rela-
tionship between six mitochondrial tRNA genes and 
BrS. We performed a methodical screening of mito-
chondrial genes in two regions, including tRNAIle, 
tRNAMet, tRNAGln, tRNAAsn, tRNAAla and tRNATrp.
Methods 
Study samples
The study was performed on 40 Iranian pa-
tients diagnosed by specialists from the center of 
Arrhythmia in Tehran, Iran. Diagnosis of type 1 
BrS was based on the presence of a prominent 
coved ST-segment elevation ≥ 2 mm or 0.2 mV at 
its peak followed by a negative T wave. Also, clini-
cal diagnostic included an electrophysiology test 
to assess of ventricular arrhythmias measurement 
and conduction times [16]. Table 1 shows the main 
characteristics of the patient population.
Also, 45 unrelated healthy individuals 
(30 males and 15 females) who were matched 
with the patients regarding sex, age (mean age: 
29.8 ± 4.5) and ethnicity and had no family his-
tory of arrhythmia were enrolled into the control 
group. They exhibited normal ECGs and no signs 
of myocardial disorders during exercise testing; 
these examinations were performed as part of 
a clinical checkup in the absence of cardiovascular 
symptoms. Recruitment of the patients and labora-
tory protocols in this study were approved by the 
Committees on the Ethics of Human Research of 
Yazd University and written informed consent was 
obtained from each participant.
Mutational analysis of mitochondrial genome
Genomic DNA from all participants was iso-
lated, including controls, from peripheral blood 
samples, using DNA isolation kit (Qiagene Co, 
Tehran, Iran). By using two pairs of specific primers 
designed from the genomic sequence of the mito-
chondrial MT-tRNA genes (4211-4521 and 5461- 
-5721), the two coding segments (320 and 279 bp, 
respectively) were amplified by polymerase chain 
reaction (PCR) (Table 2). These two segments have 
the entire sequence of the six transfer RNA genes 
(tRNA Ile, Met, Gln, Asn, Ala and Trp).
The primers were designed by primer design 
software (Primer Premier 5.0; Premier Bio soft 
Inc., Canada) and their secondary structure was 
examined using Gene Runner, version 3.05 (Hast-
ings Software Inc. Hastings, NY, USA, http://www. 
generunner.com). 
Optimized PCR conditions in a total volume 
of 25 μL mixture containing 1 × PCR buffer, 25 ng 
genomic DNA, 10 pmol/each forward and reverse 
primers, 1.5 mmol/L MgCl2, 0.2 mmol/L in each 
dNTPs, and 1 U Taq DNA polymerase were per-
formed (Cat No: YT1591, Yekta Tajhiz Azma Co, 
Table 1. Characteristics of 40 patients with  
Brugada syndrome (BrS) included in the study.
Age range at diagnosis  
(mean age)
12–63 years  
(31.4 ± 5.6)
Men/women 25/15 
Age range in men 17–63 years 
Age range in women 12–59 years
Family history of BrS 8 (20%)
Family history of sudden  
death (≤ 45 years) 
15 (37%)
Syncope 4 (10%)
www.cardiologyjournal.org 115
Mahsasadat Fallah Tafti et al., Mitochondrial tRNA mutations in Brugada syndrome
Tehran, Iran). The DNA amplification program 
included one cycle of an initial denaturation step 
at 94°C for 5 min followed by 35 cycles at 95°C for 
35 s, 57°C for 45 s, 72°C for 50 s, and a final extension 
at 72°C for 10 min. The amplified products were 
then analyzed for size on 1.5% agarose gel. 
Possible mutations were tested using single-
strand conformation polymorphism (SSCP) analy-
sis. For PCR-SSCP assay, 5 μL of PCR products 
were mixed with 10 μL SSCP loading solution (80% 
formamide/0.25% xylene cyanol FF/40% sucrose). 
DNA was made single stranded by heating at 94°C 
for 10 min, chilled immediately on ice for 2 min, 
and loaded onto a polyacrylamide/TBE 0.5 × gel. 
The gel concentrations and running conditions 
were as follows: 8% non-denaturing polyacrylamide 
gel (Sigma, Germany), 16 h, room temperature, 
5 mA. After the run, the gel was removed from 
the apparatus and the DNA bands were visualized 
through silver staining and abnormal conformers 
got sequenced from a commercial agency (Mac-
rogene Seoul, South Korea). The results of DNA 
sequencing were compared with the Cambridge 
consensus sequence.
Software and databases
In this study, online multiple sequence align-
ment was performed using Molecular Evolutionary 
Genetics Analysis (MEGA6) software (https://www.
ncbi.nlm.nih.gov/pmc/) and Blast analysis were 
used to determine the homology of the sequences 
obtained in the study and all other sequences of 
other species. This program is available at the Na-
tional Center for Biotechnology Information (NCBI) 
website (http://www.ncbi.nlm.nih.gov/Blast). 
The study of pathogenicity of the whole mtDNA 
was accomplished by the human mitochondrial ge-
nome database (Mitomap) which is briefness of poly-
morphisms and mutations in human mitochondrial 
DNA (http://www.mitomap.org/MITOMAP). Mamit-
tRNA (http://mamit-trna.u-strasbg.fr) was also used 
for detection of the structural features of mammalian 
mitochondrial tRNAs and is a helpful tool in the 
frame of human diseases linked to point mutations 
in mitochondrial tRNA genes. Finally, mitotRNAdb 
and RNAfold web server which are two database of 
mitochondrial tRNA genes (http://mttrna.bioinf.uni-
leipzig.de/mtDataOutput/) and secondary structures 
of single stranded RNA or DNA sequences (http://
rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi), were used 
in order to identify the graphical representations of 
tRNA secondary structures. 
Statistical analysis
The Fisher exact test was used to determine 
the association between mitochondrial tRNA mu-
tations and the genetic risk of arrhythmia. The 
quantitative measures in groups were presented 
as mean ± standard deviation. The statistical 
analyses were performed using the Graph Pad 
Prism software (Graph Pad Software, Inc. USA) 
and p value less than 0.05 was considered to be 
statistically significant.
Results
In a total of 40 unrelated Iranian patients and 
45 healthy subjects, PCR-SSCP analysis revealed 
aberrant conformers corresponding to 4 mutations 
in 3 transfer RNA genes (Table 3, Fig. 1). Results 
show that one heteroplasmic mutation was located 
in tRNAGln (T4377A) and according with MITOMAP 
database (Reported Mitochondrial DNA Base 
Substitution Diseases: rRNA/tRNA mutations) 
was, for first time, reported in these BrS patients. 
T4377A mutation was found in a 35-year-old  man 
with a previous history of syncope and occurred at 
D-stem of tRNA and exactly in a position that was 
highly evolutionarily conserved nucleotide of the 
corresponding tRNA (Fig. 2). This mutation was 
absent in unrelated controls.
Also, two heteroplasmic mutations in tRNAmet 
were observed: G4407A in a 40-year-old man with 
previous syncope that was reported, for first time, 
in arrhythmia and C4456T in 2 patients with synco-
pe experienced in adolescence. Previous research 
showed that variants in this region may lead to im-
pairment in tRNA 3’ end metabolism and deficiency 
Table 2. Designed primers and fragment length of each segment in polymerase chain reaction.
Primer sequence (5’-3’) Nucleotide position Tm (°C) Size (bp) Fragments
F- TATGATATATATGTCTCCATACCC 4211-4230 54 320 tRNAIle-Gln-Met
R- GAGCTTAGCGCTGTGTGATGAG 4531-4521
F- CCCTTACCACGCTACTCCTA 5461-5480 54 279 tRNAAsn-Ala-Trp
R- TTCAATCTACTTCTCCCGCC 5740-5721
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Table 3. Characteristics of four mutations in Brugada syndrome patients by sequence analysis.
Gene NT change Hetero/Homo Family history of sudden death Carrier, age/sex
tRNA-Gln T4377A Hetero Yes 45/male 
tRNA-Met G4407A Hetero Yes 55/male 
C4456T Hetero Yes 30/male
No 20/female
tRNA-Ala T5580C Homo Yes 43/male
Figure 1. The polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) gel electrophoresis 
results show two heteroplasmic mutation in tRNAGln (T4377A) and tRNAMet (G4407A) genes and a homoplasmic variant 
(5580T>C) in tRNATrp gene. The arrows indicate abnormal conformers on the gel.
Figure 2. The location of T4377A in tRNAGln; A. Cloverleaf structure of human mt-tRNAGln that is a heavy tRNA and 
transcribed from the light DNA strand and thus has a high G content; B, C. Predictions of the secondary structure of 
mt-tRNAGln with and without the mutation.
A B C
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
tRNAGln (T4377A) tRNATrp (T5580 C)
tRNAMet (G44407A)
 

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of important subunits of the respiratory chain in 
hypertension diseases, because they reported that 
oxygen consumption rate in cells containing these 
mutations decreased in comparison to the average 
level of control cases [8, 15].
The results of Mamit-tRNA site also showed 
that the positions of G4407A and C4456T muta-
tions were in acceptor stem and T-loop of tRNAmet 
respectively (Fig. 3). Both mutations affected 
conserved nucleotides and were not found in any 
of the healthy controls.
To assay whether nucleotide variations affect 
the secondary structure of mt-tRNAs, secondary 
structures of normal type and mutant tRNAs were 
predicted using the RNA fold software. All of 
3 above mutations in tRNAGln and tRNAMet cause 
instability in the secondary structure of corre-
sponding tRNAs, therefore these mutations may 
be involved in the pathogenesis of BrS.
The next mutation was a novel and homoplas-
mic T to C transition at the position 5580 mutation 
in a man with BrS but not in the healthy controls 
(Fig. 4). This variation locates at the junction of 
tRNATrp at the heavy strand and tRNAAla at the light 
strand. The 3’ end of the normal flanking sequence 
of tRNATrp gene is 5580 T/GTCTTT, whereas the 
3’ end of the mutant flanking sequence this gene is 
5580 C/GTCTTT. This nucleotide change has not 
been previously reported in various arrhythmias 
but the effect of this variation on the phenotype 
could not be assessed.
Discussion 
All 22 human mitochondrial tRNAs are en-
coded in the mtDNA [17]. The several diseases 
associated with mutations in these genes may 
manifest from reduction in aminoacylation and 
tRNA stability [18], disability in the processing 
functional tRNA and decrease of interaction with 
mitochondrial ribosomes and elongation factor Tu 
[19]. More than 350 polymorphic and pathogenic 
mutations (MITOMAP) have been observed in hu-
man mitochondrial tRNA genes [20]. However, ac-
cording to available research, few studies represent 
mutational analyses to evaluate the involvement 
of mtDNA in inherited arrhythmogenic diseases 
[21–23], and genetic studies on the mitochondrial 
Figure 4. Identification of the T5580C mutation in 3’ end 
immediately after last nucleotide (G) in mitochondrial 
tRNATrp gene. Sequence chromatogram show homo-
plasmic T5580C mutation from an affected individual. In 
cloverleaf structure of tRNATrp, arrows indicate the loca-
tion of the base change at position 3’ end. Processing 
of the mt-tRNATrp precursor has been shown by RNase 
P and 3’-endonuclease.
Figure 3. A schema of locations of C4456T and G4407A in tRNAMet; A. Cloverleaf structure of human mt tRNAMet that is 
a light tRNA and transcribed from the heavy DNA strand and have a low G content; B–D. Predictions of the secondary 
structure of mt-tRNAMet with and without the mutations.
A B C D
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DNA of BrS patients are ongoing and have yet to be 
reported. Previous studies also showed accumula-
tion of mitochondrial genome variations in patients 
affected by long QT syndrome (LQTS), an inherited 
channelopathy responsible for sudden cardiac death 
in young individuals. Moreover, ion channels are 
ATP sensitive and the heart is highly dependent 
on oxidative energy generated in the mitochondria, 
thus, it cannot be excluded that arrhythmia may 
be due to mitochondrial dysfunction. Recently, 
Stocchi et al. [23] performed association analysis 
between mtDNA alterations and 16 BrS patients. 
In their study, only one novel synonymous variant 
(C9600T) was detected in one patient. Also, they 
showed what appears to be an association between 
patients with the highest number of variants and 
four mt single nucleotide polymorphism (SNPs) 
(T4216C, A11251G, C15452A, T16126C) and the 
most severe BrS phenotype (p = 0.002). Because 
of the importance of mitochondrial genome muta-
tions, especially tRNA genes, the present study 
investigates the link between mt-tRNA mutations 
and BrS in an Iranian population.
Protein biosynthetic systems normally, have 
two tRNAMet classes. One is used specially for ini-
tiation, and the other recruits in polypeptide chain 
elongation. Mammalian mitochondria are actually 
unusual in that they have a single gene for tRNAMet, 
which functions in both the initiation and elonga-
tion phase of polypeptide synthesis. Likely, it is 
the main reason for a high degree of conservation 
in this tRNA. Therefore, this tRNAMet has critical 
significance in mitochondrial translation [24]. The 
D-loop in human tRNAMet is slightly small and lacks 
the G nucleotides that in the tertiary structure 
facilitate interactions with the T-loop. The T-stem 
has two neighboring pyrimidine: pyrimidine pairs 
and T-loop contains only six nucleotides instead of 
the normal seven that suggest human mitochon-
drial tRNAMet may have an innately weak tertiary 
structure [25]. In the present research, two inter-
esting point mutations (G4407A and C4456T) occur 
in the tRNAMet gene but methodical examinations 
of the structural and biochemical consequences of 
these mutations are missing. The novel G4407A 
mutation (Fig. 2A) results in a G6 to A change at 
the end of the acceptor stem of mtRNAMet.  Because 
this mutation leads to loss of the base pairing in 
acceptor stem, and RNA Fold results show that it 
causes changes in the structure of tRNA (Fig. 2D), 
therefore heteroplasmic and highly conserved 
G4407A mutation may cause pathogenicity through 
disruption and the formation of the acceptor stem 
and reduces correct amino acid recognition. Also 
detected was a C-to-T base change at np 4456 in 
T-loop that causes instability in the secondary 
structure of tRNA (Fig. 2C). This change was 
revealed to be heteroplasmic in two patients, and 
has also been reported as a polymorphic change in 
MITOMAP. Previous functional analysis showed 
that mutant cell lines in this region of mtRNAMet, 
had a significant reduction of oxygen consumption 
rate in patients with hypertension. Therefore, 
defecting to retain the equilibrium of oxygen con-
sumption and production may cause cardiovascular 
diseases and is probably of particular importance 
in the pathogenesis of arrhythmia.  
Also, in one patient, 4377 T>A base change 
was detected; this mutation had not been previously 
reported. This transition affected a highly conserved 
position in the tRNAGln gene (Fig. 3). The results of 
SSCP analysis also showed that this mutation was 
heteroplasmic and, consequently, it was considered 
for pathogenicity. It was determined that mismatch-
es in this stem may lead to shortening of the D-stem 
and enlargement of the D-loop (Fig. 3C) [25]. The 
analysis of potential tertiary structuresshows that 
only a few human mt tRNA species have the pos-
sibility of folding into a three dimensional structure 
through D- and T-loop interactions and that one 
of them is tRNAGln [24]. Since most tRNA families 
show high conservation within individual domains 
of the secondary structure, like D-stem, therefore 
the novel T4377A mutation can be introduced as 
a pathogenic alteration in BrS patients.
The homoplasmic 5580 T>C transition lies in 
the non-coding region immediately following the 3’ 
end of the tRNATrp. Interestingly, the thymidine at 
the 5580 position of the mitochondrial genomes is 
highly conserved among various species. Actually, the 
processing of precursors in mt-tRNAs requires the ac-
curate endonucleolytic cleavage at both 3’ and 5’ ends. 
At 3’ end, excision of tRNA from primary transcript is 
catalyzed by 3’ endonuclease, whereas at 5’ end, extra 
nucleotides are removed by RNase P [19, 26]. Thus, 
it is expected that the T-to-C transition at position 
5580 in the H-strand may lead to defective tRNATrp 
3’ end processing in the precursor transcript. It is 
known that the 5’ and 3’ end processing deficiency 
consequently of pathogenic mitochondrial tRNA 
mutations could associate with many disorders [27].
These finding would suggest that minor chang-
es in base content or structure by these substitu-
tions may result in impairment of translation and 
affect the respiratory chain which likely triggers 
cardiac diseases.
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Conclusions
Four mitochondrial tRNA base pair substitu-
tions were reported that could possibly have a sig-
nificant role in the development of BrS. It appears 
that variability at several loci will not be sufficient 
to increase arrhythmia risk but these mutations 
are associated with the risk of mitochondrial dys-
function in BrS.
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